Skip to main content

2016

2016-12-31
STOCKHOLM, December 31st, 2016. Moberg Pharma AB (OMX: MOB) has now completed the previously announced acquisition of DermoPlast® from Prestige Brands, Inc pursuant to the terms announced on December 6th. The purchase price amounted to USD 47.6M plus stock value.
2016-12-30
STOCKHOLM, December 30th, 2016. The number of shares and votes in Moberg Pharma AB (publ) (“Moberg Pharma”) has increased by 3,122,654 in December 2016. Therefore, there are in total 17,411,842 shares and votes in the company as of 30 December 2016.
2016-12-20
STOCKHOLM, December 20th, 2016. Moberg Pharma AB (OMX: MOB) announces that the company has completed the divestment of the PediaCare® brand to Strides Arcolab International Limited, UK for a total consideration of $5.6 million, whereof $0.6 million comprises inventory value.
2016-12-16
STOCKHOLM, December 16th, 2016. The prospectus regarding the admission to trading of newly issued shares in Moberg Pharma AB (publ) (“Moberg Pharma”) is now available on the company’s website, www.mobergpharma.se, and in the company’s offices, at Gustavslundsvägen 42, 167 51 Bromma. Documents incorporated by reference in the prospectus are also available in accordance with the above.
2016-12-13
STOCKHOLM, December 13th, 2016. Moberg Pharma AB (publ) (OMX: MOB) hosts a Key Opinion Leader breakfast on “Advances in Treating Onychomycosis (Nail Fungus)”. The meeting will feature a keynote presentation by Dr Aditya K. Gupta, University of Toronto, who will provide an overview of current and novel approaches to treatment in onychomycosis. Members of the Moberg management team will provide an overview of the Company’s ongoing development work with MOB015.
2016-12-07
STOCKHOLM, December 7th, 2016. Moberg Pharma AB (publ) (”Moberg Pharma”) (OMX: MOB) completes a tap issue of SEK 215M to its outstanding bond loan (ISIN: SE0007953989). The proceeds will be used as part financing of the acquisition of DermoPlast®.
2016-12-07
STOCKHOLM, December 7th, 2016. Moberg Pharma AB (publ) (”Moberg Pharma”) (OMX: MOB) has entered into a definitive agreement to acquire DermoPlast® for a purchase price of USD 47.6M plus stock value. The acquisition is financed through a directed new issue of shares in the amount of SEK 148M, an issue of corporate bonds in the amount of SEK 215M and by available cash resources.
2016-12-06
STOCKHOLM, December 6th, 2016. Moberg Pharma AB (publ) (”Moberg Pharma” or the “Company”) (OMX: MOB) considers an acquisition of DermoPlast®, a well-established Over-the-Counter brand in the U.S., from the Prestige Brands group. If the acquisition is carried out, the purchase price will be USD 47.6M plus stock value. Moberg Pharma has, based on the authorization to issue shares granted by the Company’s annual general meeting on 18 May 2016, mandated Carnegie Investment Bank to assess the preconditions for a private placement of up to 2,843,504 shares, through a so-called “accelerated book-building” procedure in order to partially finance a potential acquisition. Moberg Pharma intends to finance the remainder of the purchase price by available cash resources and a tap issue to Moberg Pharma’s outstanding bond loan.
2016-11-28
STOCKHOLM, November 28th, 2016 - Moberg Pharma AB (OMX: MOB) has obtained a waiver from its bondholders to increase flexibility in acquisition financing. The waiver provides better possibility to optimize financing of acquisitions of profitable assets.
2016-11-24
STOCKHOLM, November 24th, 2016. Moberg Pharma AB (OMX: MOB) announces that the company has entered into an agreement with Strides Pharma Inc. to divest the brand PediaCare® for a total consideration of $5 million plus the inventory value at closing.
2016-11-08
SIGNIFICANT GROWTH IN SALES AND PROFITABILITY
2016-11-08
STOCKHOLM, November 8th, 2016 - Moberg Pharma AB (OMX: MOB) summons bondholders’ meeting by way of written procedure for its outstanding maximum SEK 600,000,000 senior unsecured floating rate bonds due 2021 with a current outstanding amount of SEK 385,000,000 (the “Bonds”).
2016-11-04
STOCKHOLM, November 4th, 2016 - In accordance with the resolution of the Annual General Meeting on May 18, 2016, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18.
2016-11-01
STOCKHOLM, November 1st, 2016 - On November 8th 2016, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - September 2016. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.
2016-10-19
STOCKHOLM, October 19, 2016 -- Moberg Pharma AB (OMX: MOB) announced that the European Patent Office (EPO) has issued Patent No. 2701681 which protects BUPI, currently in development for oral mucositis. 
2016-09-28
STOCKHOLM, September 28, 2016. Moberg Pharma AB (OMX: MOB) today announced that patient enrollment has started in U.S., Canada and Germany in the Phase 3 program investigating MOB-015 for the treatment of onychomycosis.
2016-08-10
STOCKHOLM, August 10, 2016. Moberg Pharma AB (OMX:MOB) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application and that a No Objection Letter has been received from Health Canada to begin its Phase 3 trial for MOB-015 in the treatment of onychomycosis.
2016-08-09
ACQUISITION DOUBLES OPERATIONS IN THE U.S.
2016-07-08
STOCKHOLM, July 8, 2016. On June 30, Moberg Pharma AB (OMX: MOB) announced the acquisition of three Over-The-Counter brands in the U.S. from Prestige Brands, Inc. The acquisition has now been completed. The purchase price amounted to $40 million.
2016-07-05
STOCKHOLM, July 5, 2016. Moberg Pharma AB (OMX: MOB) today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MOB-015 in the treatment of onychomycosis. In addition, the Company has submitted Clinical Trial Applications to the regulatory authorities in Germany, Poland and Canada.
2016-06-30
STOCKHOLM, June 30, 2016. Moberg Pharma AB (OMX: MOB) has completed a tap issue of SEK 85 million to its outstanding bond loan (ISIN: SE0007953989). The proceeds will be used as part financing of the acquisition of New Skin®, Fiber Choice® and PediaCare® and for general corporate purposes.
2016-06-30
STOCKHOLM, June 30, 2016. The number of shares and votes in Moberg Pharma AB (publ) has increased by 71,666 to 14,289,188 during June 2016. Therefore, there are in total 14,289,188 shares and votes in the company as of June 30, 2016.
2016-06-30
STOCKHOLM, June 30, 2016. Moberg Pharma AB (OMX: MOB) has signed an agreement to acquire New Skin®, Fiber Choice® and PediaCare®, three well-established Over-The-Counter brands in the U.S. from Prestige Brands, Inc. In the latest 12 months ending March 31, 2016, the Net sales of these brands was approximately $24.4 million. The purchase price is $40 million and Moberg Pharma expects the acquired brands to contribute to its EBITDA with approximately $5 million for the 12 months following closing of the transaction. The acquisition is financed by available cash resources and a tap issue to Moberg’s outstanding bond loan.
2016-06-28
STOCKHOLM, June 28th, 2016. Moberg Pharma AB (OMX: MOB) today announced that its partner, Menarini Asia-Pacific, recently initiated the launch of Emtrix® in Japan and that the initial consumer response has been strong. In the U.S., Kerasal Nail® has further increased its market share following the recent repositioning of the brand.
2016-05-18
STOCKHOLM, MAY 18th, 2016. Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Wednesday, May 18, 2016 in the Company´s premises in Bromma.
2016-05-18
STOCKHOLM, May 18th, 2016. Moberg Pharma AB (OMX: MOB) provided an update on the intellectual property portfolio protecting MOB-015, the Company’s investigational topical treatment for onychomycosis (nail fungus). Patents have recently been granted and Notice of Allowances received in multiple territories worldwide. The patents granted are expected to be in effect until 2032.
2016-05-10
POSITIVE PHASE 2 DATA FOR BUPI AND GROWTH FINANCING SECURED
2016-04-19
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Monday, May 18, 2016 at 5:00 p.m. (CET) in the Company´s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden. To celebrate Moberg Pharma’s 10 year anniversary, shareholders are invited to a cocktail reception directly after the AGM, i.e. approximately at 6:00 p.m. Welcome!
2016-04-19
Moberg Pharma´s Annual Report for 2015 has been published and is available on www.mobergpharma.com
2016-04-04
STOCKHOLM, April 4th, 2016. Moberg Pharma AB (OMX: MOB) announces that the company has completed the divestment of the Jointflex, Fergon and Vanquish brands to Strides Pharma Inc. for a total consideration of $10.4 million, whereof $0.4 million comprises inventory value.
2016-03-22
STOCKHOLM, March 22, 2015. Moberg Pharma AB (OMX: MOB) today announced a decision to initiate development of BUPI through phase III. The decision follows an evaluation of the complete data set from the recent phase II study for BUPI.
2016-03-22
STOCKHOLM, March 22, 2015. Moberg Pharma AB (OMX: MOB) today announced that Moberg Pharma and Cadila Pharmaceuticals Limited – one of the largest healthcare manufacturing groups in India – entered a Development and License Agreement for BUPI – a novel lozenge formulation of bupivacaine for pain management in oral mucositis patients.
2016-03-07
STOCKHOLM, March 7, 2016. Moberg Pharma AB (OMX: MOB) announces that the company has entered into an agreement with Strides Pharma Inc. to divest the brands Jointflex, Fergon and Vanquish for a total consideration of $10 million plus the inventory value at closing.
2016-02-23
STOCKHOLM, February 23rd 2016. Moberg Pharma AB (publ) (”Moberg Pharma” or ”the company", OMX: MOB)  publishes a bond prospectus and applies for listing on Nasdaq Stockholm of its bond loan.
2016-02-18
STOCKHOLM, February 18th, 2016. Moberg Pharma AB announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2016.
2016-02-17
STRONG QUARTER FOR OUR INNOVATION ENGINE
2016-01-25
STOCKHOLM, January 25th, 2016. Moberg Pharma AB (OMX: MOB) announces that the company has decided to issue a five-year senior unsecured bond loan in the amount of SEK 300 million with maturity on January 29th, 2021.
2016-01-21
STOCKHOLM, January 21st, 2016. Moberg Pharma AB (OMX: MOB) announces that the company intends to issue a bond and has engaged Carnegie Investment Bank and Swedbank as financial advisors. The issue proceeds are intended to be used for general corporate purposes, including accretive add-on acquisitions.
2016-01-11
STOCKHOLM, January 11, 2016. Moberg Pharma AB (OMX: MOB) announces positive top-line results from a phase II-study with BUPI for the treatment of pain due to oral mucositis in patients with head and neck cancer. BUPI achieved a statistically significant reduction in pain.
2016-01-08
Katja Bergqvist replaces Elisabet Jamal Bergström as representative for Handelsbanken in Moberg Pharma’s Nomination Committee